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We analyzed hospitalizations in England from April 1, 1989,
to March 31, 1998, and identified approximately 700 cases, 46
fatal, from viral encephalitis that occurred during each year;
most (60%) were of unknown etiology. Of cases with a diagno-
sis, the largest proportion was herpes simplex encephalitis.
Using normal and Poisson regression, we identified six possi-
ble clusters of unknown etiology. Over 75% of hospitalizations
are not reported through the routine laboratory and clinical noti-
fication systems, resulting in underdiagnosis of viral encephali-
tis in England. Current surveillance greatly underascertains
incidence of the disease and existence of clusters; in general,
outbreaks are undetected. Surveillance systems must be
adapted to detect major changes in epidemiology so that timely
control measures can be implemented. 
outine laboratory reports and statutory clinical notifica-
tions of infectious diseases are a source of viral encepha-
litis surveillance in England; however, these methods are
considered to be incomplete. Hospital episode statistics record
hospital admissions of viral encephalitis; although not timely
enough for surveillance, these statistics can be used to monitor
the distribution of admissions attributed to viral encephalitis
by hospital physicians. 
Most cases of viral encephalitis in the U.K. are thought to
be rare complications of common infections. Herpes simplex
virus (hereafter referred to as herpes) is the virus most often
associated with encephalitis (1–3). Other viruses known to
cause encephalitis include varicella-zoster virus 1 (VZV),
measles virus, rubella virus, Lymphocytic choriomeningitis
virus, cytomegalovirus, Epstein-Barr virus, and the adenovi-
ruses (4–6). Cases of encephalitis attributed to arthropod-
borne viruses (arboviruses) are common in certain areas of the
world, but only rare, imported cases have been reported in the
U.K. (7,8). 
Clinical diagnosis of viral encephalitis is based on symp-
toms such as fever, headache, and altered mental state; how-
ever, a definitive diagnosis of viral encephalitis relies on
detecting the virus in cerebrospinal fluid or brain. The use of
virologic investigation has been inconsistent in England. Virus
isolation, formerly the standard criterion for diagnosis, is
steadily being replaced by polymerase chain reaction (PCR)
(9–11), which is more sensitive and provides a more rapid
result.  However, PCR was not widely used at the time of this
study (9,12,13). 
The demonstration of specific intrathecal antibody, either
by detecting a raised antibody index or by detecting specific
oligoclonal bands in cerebrospinal fluid, provides evidence of
recent neurologic infection. When combined with an appropri-
ate clinical picture, this demonstration is considered diagnostic
(14). A noninvasive investigation such as magnetic resonance
imaging (MRI) is also diagnostic (15). Serologic confirmation
based on a fourfold rise in the level of antibody to the virus in
the acute- and convalescent-phase blood samples or the dem-
onstration of an intrathecal antibody response also provides
evidence of recent infection.
The accurate diagnosis of viral encephalitis is important,
particularly so for herpes and VZV encephalitis because sev-
eral effective antiviral drugs are widely available for treatment
(1,16,17). Accurate diagnosis is also required to increase the
usefulness of surveillance so that the pattern of viral encepha-
litis cases can be monitored, especially since concern is
increasing about the potential problems posed by new and
reemerging infections (18). As new treatments and vaccines
for existing viral infections become available, good surveil-
lance data are required to accurately describe the public health
cost of viral encephalitis, develop appropriate vaccination
strategies, and perform treatment algorithms (available from:
URL: http://www.isabel.org.uk/) (19,20). 
This study describes the epidemiology of viral encephalitis
in England from 1989 to 1998 by using hospital episode statis-
tics (available from: URL: http://www.doh.gov.uk/hes/) and
evaluates routine surveillance systems in terms of their ability
to quickly and accurately monitor sporadic cases and clusters.
We also consider possible future surveillance methods.
Methods
Data Sources
Hospital episode statistics provide information on hospital
care in National Health System hospitals in England. No case
definition is available for viral encephalitis, but diagnosis is
generally based upon clinical evidence of viral encephalitis
and available confirmatory laboratory data as recorded in the
patient’s medical record at the time of discharge. The diagno-
sis is recorded by using the World Health Organization Inter-
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national Classification of Disease (ICD) codes. These codes
allow for specific (clinical and laboratory evidence) and non-
specific (only clinical evidence) diagnoses. We analyzed
reports of hospital admissions for all adults and children (<17
years of age) from April 1, 1989, to March 31, 1998. Cases of
viral encephalitis were identified by ICD ninth edition (ICD-9)
codes for admissions in 1989–1995 and 10th edition (ICD-10)
codes for admissions in 1995–1998. Patient records were also
extracted if any of seven diagnostic codes mentioned a diagno-
sis of viral encephalitis (Table 1). Since no ICD-9 code has
been defined for VZV or adenovirus encephalitis, any VZV or
adenovirus infection code accompanied by a code for nonspe-
cific viral encephalitis before 1995 was included in the analy-
sis. Multiple episodes for one patient were considered to be a
single infection if <1 month elapsed between episodes.
The second data source was laboratory reports sent to the
Communicable Disease Surveillance Centre from the Public
Health Laboratory Service (PHLS), National Health System,
and private laboratories in England. All laboratory reports of
isolates of viruses known to cause encephalitis from January 1,
1990, to December 31, 1998, were extracted from LabBase
(the PHLS laboratory network electronic database). From
these reports, infections thought to be associated with enceph-
alitis were identified. Data extracted included laboratory
reports in England with specimen date between January 1,
1990, and December 31, 1998, of adenoviruses, herpes, VZV,
cytomegalovirus, lymphocytic choriomeningitis virus,
Epstein-Barr virus, measles, mumps, or rubella detected in the
cerebrospinal fluid, or adenovirus, herpes, VZV, cytomegalov-
irus, lymphocytic choriomeningitis virus, Epstein-Barr virus,
measles, mumps, or rubella in any specimen with an encepha-
litis diagnosis in the feature or comment field.
An additional data source was the Notifications of Infec-
tious Disease System (NOIDS) (available from: URL:
www.phls.co.uk/facts/NOIDS/noid.htm). Clinically diagnosed
cases of viral encephalitis are reported weekly as acute, infec-
tious encephalitis to consultants in Communicable Disease
Control and collated by the Communicable Disease Surveil-
lance Centre. Data collected included the week of the report
and patients’ age, sex, and local health authority of residence.
Reports from 1989 through 1998 were available for analysis. 
The final source was certified deaths reported to the Office
of National Statistics. Information about deaths attributed to
viral encephalitis from January 1, 1993, to December 31,
1998, in England was available from Office of National Statis-
tics data held by the Communicable Disease Surveillance Cen-
tre. All deaths were coded with an ICD-9 designation.
Analysis
We investigated trends in hospitalizations of viral encepha-
litis by fiscal year, using 1995 mid-year resident population
estimates for England to calculate rates. Single- and multi-
variable regression was used to compare rates by fiscal year,
age group (<1, 1–4, 5–9, 10–16, 17–24, 25–34, 35–44, 45–54,
55–64, and >65 years of age), sex, and regional health author-
ity of hospital (Anglia and Oxford, North West, South and
West, Trent, North Thames, Northern and Yorkshire, South
Thames, and West Midlands). We initially investigated evi-
dence of clustering of case-patients with a nonspecific diagno-
sis by comparing weekly totals of hospitalizations of
nonspecific viral encephalitis to the weekly overall mean num-
ber during the study period. Possible clusters were considered
to have occurred when the weekly total was >2.58 and >3.3
standard deviations from the mean, corresponding to 99.5%
and 99.95% upper prediction limits, respectively. In addition,
we used Poisson regression to calculate an upper weekly and
monthly prediction limit (at 99.5% and 99.95%) for each hos-
pital’s district health authority. Any weekly or monthly count
greater than or equal to the limit in each district was flagged as
a possible outbreak. We compared NOIDS and laboratory
reports to hospital episode statistics to determine the level of
underreporting in each.
Results
Hospital Episode Statistics
From April 1, 1989, to March 31, 1998, a total of 6,414
adults and children were hospitalized in England with a diag-
Table 1. Diagnostic codes used to identify cases of viral encephalitis in hospital episode statistics
Encephalitis diagnosis ICD-9a ICD-10a
Specific diagnosis: Exotic virus 0620–0629, 0630–0638, 064, 0661, 0622, 3233 A830–A839, A840–A849, A852
Herpes simplex virus 0543 B004
Varicella-zoster virus 1 Undefined B011, B020
Measles virus 0550 B050
Mumps 0722 B262
Rubella 0560, 0567 B060
Lymphocytic choriomeningitis virus 0490, 3126 A872
Adenovirus Undefined A851
Other 0498, 3234 A858
Nonspecific diagnosis: Unspecified 0499, 3239 A86, G051
aICD, International Classification of Disease.RESEARCH
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nosis of viral encephalitis (Table 2), a figure that corresponds
to an estimated annual rate of 1.5 cases per 100,000 popula-
tion. Most of these patients had a nonspecific infection. A spe-
cific diagnosis was recorded for 2,574 patients, the largest
proportion of which (52%) had herpes infection. The other
diagnoses included 18% with “other” and 13% with VZV. The
remaining 223 included patients with encephalitis associated
with measles, mumps, rubella, exotic viruses (arboviruses),
and Lymphocytic choriomeningitis virus infections. 
A total of 2,734 cases were diagnosed in children (includ-
ing 35 in neonates), corresponding to an estimated annual rate
of 2.8 per 100 000 children and accounting for 43% of all hos-
pitalizations of viral encephalitis. An estimated 21% declining
trend occurred in the rate over the 9 years, although this
decline is not significant (p=0.065). Over half (51%) of the
hospitalizations of children occurred for those <5 years of age,
with the highest rate (8.7/100 000) for infants <1 year of age.
The rate remained highest for infants throughout the 9 years of
the study; however, we found some variation between the age
groups in the time trends that approached significance
(p=0.063), with the largest decline in adolescents ages 10–16
years (estimated to be 37%) and the smallest in toddlers 1–4
years of age (estimated to be 4%). Little difference appeared in
the rate in male children compared to female children overall
(2.9 and 2.8/100,000 children; p=0.23); furthermore, the trend
over the 9 years did not differ by sex (p=0.63).
In adults, 3,680 patients diagnosed with encephalitis were
hospitalized, which approximates an annual rate of 1.1 per 100
000 adults with no overall significant trend over time (p=0.17).
No significant variation appeared in the rate between the age
groups overall, but the highest rate occurred in those aged 17–
24 years at approximately 1.2 per 100,000. The change in the
incidence of hospitalized case-patients over time varied
between age groups (p=0.0016); this change was mostly attrib-
utable to an increase of 46% in the rate in elderly case-patients
(>65 years of age) with no significant changes in other age
groups. We found no difference in the overall rate of male
case-patients compared to female case-patients (1.1 and 1.0/
100,000 adults; p=0.12); furthermore, the trend over the 9
years did not differ by sex (p=0.74). 
The rate between the regional health authority of hospitals
did not vary significantly overall (p=0.55); however, the larg-
est proportion of cases (16%) and highest rate (1.63/100 000
population) were hospitalized in the North Thames region.
The trend over the 9 years did not significantly vary by
regional health authority (p=0.13).
The proportion of cases with a specific diagnosis was sig-
nificantly lower in children (33%) than adults (45%)
(p<0.001). In children, this proportion varied throughout the
study (p<0.001); it was at a minimum of 23% during 1992–
1993 and a maximum of 50% during 1996–1997. Children
with a specific diagnosis were significantly younger than those
without (mean age of 5 vs. 6.1 years; p<0.001) but did not dif-
fer in terms of sex. In adults, the proportion with a specific
diagnosis did not vary significantly by year. Those with a spe-
cific diagnosis were significantly older compared to those
without (mean age 49 vs. 43 years; p<0.001) but did not differ
in terms of sex. The proportion of all cases with a specific
diagnosis varied significantly by region, ranging from 34% in
Trent to 47% in Northern and Yorkshire (p<0.001). The
regions of Northern and Yorkshire had the highest proportion
of herpes encephalitis (28.35%); in comparison, Trent had
Table 2. Hospitalizations of viral encephalitis patients by diagnosis and fiscal year of admission, April 1, 1989–March 31, 1998, England
Diagnosis
Date of admission by fiscal yr
1989–90 1990–91 1991–92 1992–93 1993–94 1994–95 1995–96 1996–97 1997–98 Total
E x o t i c 337759 2 0 736 4
Herpes viruses
   Herpes simplexa 138 163 170 175 172 168 120 147 166 1,419
   Varicella zoster 8 17 13 8 8 6 94 99 80 333
Others
    M e a s l e s 1 6 8878 2 3 7548 6
    M u m p s 1 2 523102323 0
    R u b e l l a 5331255112 6
    LCMVb 002000023 7
    Adenoviruses 19 15 21 14 17 14 12 10 7 129
    Otherc 47 75 56 51 62 48 58 46 37 480
Total specified viral infection (%) 248 (40) 289 (40) 282 (37) 266 (37) 275 (33) 273 (36) 318 (47) 320 (48) 303 (47) 2,574 (40)
Unspecified viral infection (%) 379 (60) 422 (60) 488 (63) 461 (63) 551 (67) 480 (64) 365 (53) 351 (52) 343 (53) 3,840 (60)
Total (%) 627 (100) 711 (100) 770 (100) 727 (100) 826 (100) 753 (100) 683 (100) 671 (100) 646 (100) 6,414 (100)
aHerpes simplex virus is undefined after 1995–1996 and recorded thereafter as herpes.
bLCMV, Lymphocytic choriomeningitis virus.
cBoth “other” and “unspecified” are included because both groups existed from 1995 to 1996 onward.Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 237
RESEARCH
21.4%, and North West (the region with the lowest proportion)
had 18%.
In hospitalized case-patients, 417 deaths were identified
during the 9 years of study. The severity of cases was com-
pared by using a crude case-fatality rate and mean length of
stay (Table 3). The overall case-fatality rate was 6.5 per 100
cases, and the mean length of stay was 17.5 days. Consider-
able variation appeared in case-fatality rate and mean length of
stay among the different diagnoses. Herpes encephalitis had
the highest overall case-fatality rate and mean length of stay
and was considered to be the most severe diagnosis. In chil-
dren, the overall case-fatality rate was 2.3 per 100 cases (95%
confidence interval [CI] 1.8 to 3), 1.9 per 100 cases of herpes
(95% CI 0.7 to 4), and 2.1 per 100 cases of viral encephalitis
without a specific diagnosis (95% CI 1.5 to 2.8). The mean
length of stay for children was 10.9 days, increasing to 11.6
days for patients without a diagnosis specified and 13.2 days
for patients with herpes encephalitis. In adults, the case-fatal-
ity rate was higher than children at 9.7 per 100 cases (95% CI
8.8 to 10.7), 12.5 in herpes encephalitis (95% CI 10.4 to 14.3),
and 8.5 per 100 cases without a diagnosis specified (95% CI
7.2 to 9.7). The mean length of stay for adults was 22.4 days,
which increased to 30 days for those with herpes or “other”
diagnoses compared with 17 days for cases without a diagno-
sis specified. 
Evidence of Clustering
For nonspecific cases of viral encephalitis, the frequency
of hospitalizations (noted by week) indicated that some clus-
tering of undiagnosed viral encephalitis had occurred during
the 9 years of study since the upper prediction limits at 99.5%
and 99.95% were exceeded in 6 weeks. Three of the six clus-
ters occurred closely together in 1993 (weeks 45, 47, and 51),
which suggests an overall period of higher incidence during
this time. The Poisson regression model suggested clustering
of encephalitis of unknown cause in district health authorities,
and the total number of cases occurring in a week was greater
than the prediction limit at 99.95% in three districts. The
model did not identify any clusters when the period was
extended to those occurring within 1 month. 
Comparison of Data Sources
Significant underreporting of viral encephalitis was seen in
the routine systems when compared to hospital episode statis-
tics. A total of 215 cases of acute infectious encephalitis were
identified through NOIDS between April 1, 1989, and March
31, 1998, compared to 6,414 identified in hospital episode sta-
tistics. This disparity implies that almost all (97%) hospital-
ized cases were not formally reported. 
A total of 599 cases of viral encephalitis were identified
through the laboratory reporting system from January 1, 1990,
to December 31, 1998. Fifty nine per cent of these cases were
herpes (86 herpes simplex virus 1, 48 herpes simplex virus 2,
and 219 subtype not known), 21% varicella and 4% adenovi-
rus. The remaining 16% of cases included 26 cytomegalovirus,
15 Epstein-Barr virus, 20 measles virus, and 13 mumps. Of
herpes encephalitis, 19% (66/353) of cases occurred in chil-
dren and 4.8% (17/353) in neonates. Of herpes encephalitis
cases in neonates that were typed, seven were herpes simplex
virus 2 and two were herpes simplex virus 1. 
The number of laboratory reports of viral encephalitis
increased from 52 in 1990 to 80 in 1991, falling to 55 in
1993, and rising again to a peak of 104 in 1998. Excluding
those cases for which no specific ICD-9 or ICD-10 code
exists and which could not have been identified in hospital
episode statistics, 558 cases of viral encephalitis were
reported through the laboratory system from January 1, 1990,
to March 31, 1998. This total represents approximately 71%
underreporting when compared to 1,867 hospitalizations of
viral encephalitis with a specific infection reported (Table 4).
Table 3. Hospitalizations of viral encephalitis patients, deaths, and duration of stay, England, April 1, 1989–March 31, 1998a
Diagnosis No. of cases No. of deaths (%) Case-fatality rate/100 cases 95% CI Length of stay in days 95% CI
Exotic 64 1 (0.2) 1.6 0.01 to 8.6 16.5 7.5 to 25.5
Herpes viruses
    Herpes simplex virus 1,419 141 (33.8) 10 8.4 to 11.6 26.6 23.6 to 29.6
    VZV 333 25 (6.0) 7.6 4.9 to 10.9 11.8 10.0 to 13.4
Others
    Measles 86 1 (0.2) 1.2 0.01 to 6.3 6.8 3.1 to 10.5
    Mumps 30 1 (0.2) 3.3 0.01 to 15.8 4.1 2.9 to 5.3
    Rubella 26 2 (0.5) 7.7 0.9 to 25.1 76.0 0.0 to 174.0
    LCMV 7 0 (0.0) 0 7.2 2.1 to 12.3
    Adenoviruses 129 6 (1.4) 4.7 1.8 to 9.8 8.5 6.8 to 10.2
    Other 480 33 (7.9) 6.8 4.7 to 9.4 18.8 12.4 to 25.1
Unspecified viral infection 3,840 207 (49.6) 5.5 4.7 to 6.2 14.8 13.7 to 15.9
Total 6,414 417 (100) 6.5 5.9 to 7.1 17.5 16.4 to 18.6
aCI, confidence interval; VZV, varicella-zoster virus 1; LCMV, Lymphocytic choriomeningitis virus.RESEARCH
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This underreporting varied by virus, ranging between 28%
and 100%. 
Hospital episode statistics showed an underascertainment
of deaths. Viral encephalitis was given as the final underlying
cause of 622 deaths certified from January 1, 1993, to March
31, 1998. In that comparative period, hospital episode statis-
tics showed 259 deaths, only 42% of those formally certified
and reported to the Office of National Statistics. Most (483/
622) certified deaths from viral encephalitis did not have a
specific diagnosis; however, 139 deaths did. We compared the
139 deaths to the 112 identified in hospital episode statistics
for which a specific diagnosis was recorded (Table 4).
Discussion
The public health impact of viral encephalitis in England
cannot be clearly defined with existing data sources. During
our study of viral encephalitis in England, we found that more
cases of viral encephalitis were identified in hospital episode
statistics than in routine surveillance systems. Most cases
requiring hospitalization are viral encephalitis with unknown
etiology; of those cases with a specific diagnosis recorded,
herpes is the most common cause. Adults account for the
majority of case-patients, and rates have increased in those
aged >65 years. Our analysis of cases of viral encephalitis
without a specific diagnosis in hospital episode statistics iden-
tified clusters that would have otherwise gone undetected.
Timely hospital episode statistics would provide a more com-
prehensive surveillance than any existing system. 
The coding system used for the hospital diagnoses
recorded in hospital episode statistics changed from ICD-9 to
ICD-10 beginning on April 1, 1995. In some cases, diagnoses
became less specific and in some cases more specific (e.g.,
herpes simplex virus was coded to herpes while VZV encepha-
litis had a specific ICD-10 code from 1995). In this study, we
made some effort to compensate by including hospitalized
cases with a diagnosis of chickenpox and an unspecified viral
encephalitis infection. The change in coding did not appear to
cause any major changes in the total number of hospitalized
viral encephalitis cases. 
Why are so few diagnoses in hospital episode statistics
specific? Whether an appropriate investigation has been car-
ried out, the extent to which a specific diagnosis is sought, and
the quality of medical records affect the recording of specific
diagnoses in hospital episode statistics. Appropriate investiga-
tion is limited by the diagnostic techniques available; virus
isolation from cerebrospinal fluid or the brain can delay a
diagnosis because culturing is slow, sensitivity may be poor,
and obtaining specimens may require special techniques.
Determining the virus causing the encephalitis may not be
seen as essential if all patients diagnosed with viral encephali-
tis are routinely given acyclovir, regardless of the virologic
diagnosis. Regional variation in the proportion of hospitaliza-
tions without a specific diagnosis suggests that local labora-
tory practice or investigation by clinicians may differ. A
nonspecific diagnosis is recorded in hospital episode statistics
if the laboratory results arrive after discharge. During the
period of study, the rapid and highly sensitive PCR test was
not widely used in England; however, as the test becomes
more widely available, the proportion of cases with a specific
diagnosis in hospital episode statistics may increase. In this
study, we found that adults with a specific diagnosis were
older than those without a diagnosis, which is likely to reflect
the age distribution of herpes, VZV, and other specific viral
encephalitis diagnoses. A lower case-fatality rate, however,
and mean length of stay in hospital suggests that these infec-
tions without a specific diagnosis are less severe. 
With the emergence of new diseases and availability of
vaccines for some viruses, determining the cause of these
infections is increasingly important (19,21–25). Information
on etiology would also increase the specificity of cluster detec-
tion. In the past, routine data sources have been used alongside
hospital episode statistics to determine the likely cause of hos-
Table 4. A comparison of cases and deaths attributed to viral encephalitis with a specific diagnosis identified through hospital episode statistics, 
the laboratory reporting system, and the Office of National Statistics, Englanda
Diagnosis
Cases Deaths
HESb Laboratory reportsb
Estimate of underreporting 
in laboratory reports (%) HESc ONSc
Estimate of underreporting 
in HES (%)
Herpes 1,308 353 73 85 104 22
VZV 325 124 62 24 34 42
Measles 71 43 39 0 1 100
Mumps 18 13 28 2 0 0
Rubella 23 1 96 0 0 -
LCMV 7 0 100 0 0 -
Adenoviruses 115 24 79 1 0 0
Total 1,867 558 70 112 139 24
aHES, hospital episode statistics; Herpes, herpes simplex virus; VZV, varicella-zoster virus 1; LCMV, Lymphocytic choriomeningitis virus.
bJanuary 1, 1990–March 31, 1998.
cJanuary 1, 1993–March 31, 1998.Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 239
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pitalizations without a specific diagnosis (26). These methods
depend on seasonality of the viruses and are thus inappropriate
for encephalitis. 
To minimize overestimating the public health cost of viral
encephalitis, multiple consultant episodes of care for a patient
were counted as a single infection if <1 month elapsed
between each. Hospital episode statistics do not include strict
case definitions, which could also lead to overestimating. For
example, between January 1, 1990, and March 31, 1998, a
total of 71 cases of measles were reported in hospital episode
statistics, most in children <5 years of age. These cases are
unlikely to be true measles encephalitis since measles was rare
in the 1990s following the introduction of the combined mea-
sles, mumps, and rubella vaccine in 1988 (27). Furthermore,
none of the laboratory reports of measles encephalitis in this
study were in infants, and only three were in children (aged 7,
11, and 14 years). The laboratory reports may also be overesti-
mated. Cases have been included in the laboratory data based
on a single high serum antibody titer. Had a stricter case defi-
nition been used, as has been suggested for measles (28), even
fewer cases of viral encephalitis would have been identified in
the laboratory system.
Hospital episode statistics identified a lower number of
deaths from viral encephalitis than the number reported rou-
tinely to the Office of National Statistics. Deaths in hospital
episode statistics are known to be incomplete since patients
with encephalitis may die after discharge, and the death may
be recorded in an episode that does not include encephalitis as
a diagnosis and was thus missed in the data extraction (29). 
Some epidemics of encephalitis in England are undetected
in routine surveillance systems and undiagnosed in hospital
episode statistics. This situation suggests the potential for
another emerging infectious disease, such as West Nile infec-
tion, to occur in the U.K.; existing routine surveillance sys-
tems would be incapable of detecting this (30–32). Levels of
disease in England are not as high as reported in a similar
study in the United States (33); however, the proportion with-
out a specific diagnosis is comparable. To improve surveil-
lance, clinicians must be encouraged to report viral
encephalitis, although notifications are not specific. Other
existing surveillance systems, such as the British Pediatric
Surveillance Unit (available from: URL: http://
www.bpsu.inopsu.com/), could be modified to include a spe-
cific diagnosis of viral encephalitis. Alternatively, a sentinel
surveillance system using existing laboratory networks and
offering screening for a wide range of viruses could provide
more accurate and timely data. 
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